MedCap AB (MCAP) AI Stock Analysis

• Market Cap: kr7.25B
• Dividend Yield: N/A
• Average Volume (3M): 17.28K
• Price to Earnings (P/E): 35.8
• Beta (1Y): 0.50
• Revenue Growth: 10.18%
• EPS Growth: -1.08%
• Country: SE
• Employees: 570
• Sector: Healthcare
• Sector Strength: 39
• Industry: Asset Management
• EPS (TTM): 3.30
• Shares Outstanding: 15,044,353
• 10 Day Avg. Volume: 17,892
• 30 Day Avg. Volume: 17,284
• PEG Ratio: 1.25
• Price to Book (P/B): 3.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 77.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: kr469.00 ▲(0.11%Upside)

MedCap AB's strong financial performance is the most significant factor supporting the stock score, showcasing robust revenue growth and solid profitability. However, the technical analysis indicates bearish trends and potential overvaluation concerns, affecting the overall score.

MedCap AB Business Overview & Revenue Model

Company Description

MedCap AB (MCAP) is a Sweden-based investment company that specializes in acquiring and developing small to medium-sized enterprises within the life sciences sector. The company focuses on businesses with significant growth potential in pharmaceuticals, biotechnology, medical technology, and healthcare services. MedCap leverages its industry expertise to enhance the value of its portfolio companies, driving innovation and operational improvements.

How the Company Makes Money

MedCap AB makes money primarily through the acquisition and development of companies in the life sciences sector. The company invests in businesses with potential for growth and profitability, and then works to improve their operational efficiencies and market positions. Revenue is generated through the appreciation of these investments, allowing MedCap to realize profits when these companies are sold or go public. Additionally, MedCap may earn income through dividends and distributions from its portfolio companies. Strategic partnerships and the careful selection of high-potential businesses are significant factors that contribute to the company's earnings.

MedCap AB Financial Statement Overview

Summary

MedCap AB demonstrates strong financial health with robust revenue growth, solid profitability margins, and effective cash flow management. The company has a conservative balance sheet with low leverage and strong equity financing, although potential cost pressures and liquidity warrant monitoring.

Income Statement

MedCap AB has demonstrated robust revenue growth, with a consistent increase in total revenue over the years. The TTM period shows a gross profit margin of 47.1% suggesting strong control over cost of goods sold. The net profit margin for the TTM is 11.0%, indicating healthy profitability. The EBIT and EBITDA margins of 13.9% and 20.7%, respectively, highlight efficient operational management. However, a slight decline in EBIT and EBITDA margins compared to the previous annual period points to potential cost pressures.

Balance Sheet

The company's balance sheet reflects a solid financial position with a debt-to-equity ratio of 0.27 during the TTM, signifying low leverage. The return on equity for TTM stands at 15.4%, showcasing effective use of shareholder funds to generate profit. The equity ratio of 64.3% indicates a stable capital structure with significant equity financing. However, the decreasing trend in cash and cash equivalents may warrant attention for liquidity management.

Cash Flow

MedCap AB has shown a positive operating cash flow to net income ratio of 1.60 for TTM, indicating strong cash generation relative to its net income. The free cash flow to net income ratio is 1.29, reflecting efficient capital expenditure management. Despite a decline in free cash flow growth rate, the company maintains a healthy cash flow position supporting its operations and future investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.84B	1.81B	1.59B	1.11B	916.30M	817.40M
Gross Profit	865.60M	1.06B	926.40M	462.40M	369.80M	326.60M
EBITDA	381.50M	396.00M	327.40M	237.30M	186.80M	147.80M
Net Income	201.70M	207.40M	172.20M	117.60M	96.50M	60.90M
Balance Sheet
Total Assets	2.03B	1.99B	1.66B	1.43B	1.17B	1.08B
Cash, Cash Equivalents and Short-Term Investments	315.20M	370.10M	188.20M	236.20M	139.70M	146.50M
Total Debt	347.30M	358.00M	261.20M	340.00M	256.90M	263.70M
Total Liabilities	721.00M	703.20M	635.10M	570.60M	471.80M	479.30M
Stockholders Equity	1.31B	1.28B	1.02B	856.30M	696.00M	595.70M
Cash Flow
Free Cash Flow	260.90M	293.80M	188.70M	41.20M	55.40M	91.20M
Operating Cash Flow	323.10M	360.00M	228.00M	85.50M	116.30M	115.60M
Investing Cash Flow	-171.10M	-128.80M	-152.30M	-56.10M	-64.80M	-131.90M
Financing Cash Flow	-57.40M	-46.10M	-119.70M	61.20M	-64.10M	144.50M

MedCap AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 468.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCAP, the sentiment is Positive. The current price of 468.5 is above the 20-day moving average (MA) of 437.95, above the 50-day MA of 435.74, and above the 200-day MA of 464.99, indicating a bullish trend. The MACD of 12.98 indicates Negative momentum. The RSI at 69.86 is Neutral, neither overbought nor oversold. The STOCH value of 94.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MCAP.

MedCap AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SVOL.B	64 Neutral	€5.82B	13.31	-3.12%	3.05%	―	―
IDUN.B	63 Neutral	kr4.02B	101.87	7.13%	0.29%	2.42%	20.90%
MCAP	62 Neutral	kr7.25B	35.78	16.42%	―	10.18%	-1.08%
LINC	57 Neutral	kr4.42B	18.08	5.76%	―	37.32%	-39.07%
BURE	56 Neutral	kr21.49B	185.23	0.27%	0.95%	13.61%	-97.82%
Sector *	50 Neutral	kr5.44B	12.69	-80.61%	5.08%	37.36%	27.71%